Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 14/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 5/20 | 0.48 |
| ▸ | KLK1 | P06870 | 3/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 4/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.41 |
| ▸ | PLA2G2E | Q9NZK7 | 3/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6690357 | 0.92 | PLA2G2A (0.51) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL6770631 | 0.91 | PLA2G2A (0.46) | PLA2G2APLA2G1BKLK1KLKB1PLA2G10 | |
| SCHEMBL6774185 | 0.90 | TP53 (0.47) | PLA2G2APLA2G1BKLK1KLKB1F10 | |
| SCHEMBL6773103 | 0.90 | PLA2G2A (0.44) | PLA2G2APLA2G1BKLK1PLA2G10PLA2G5 | |
| SCHEMBL6691732 | 0.89 | ADRA1D (0.44) | PLA2G2AF10 | |
| SCHEMBL6777891 | 0.89 | PLA2G2A (0.49) | PLA2G2APLA2G1BKLK1KLKB1PLA2G10 | |
| SCHEMBL6773912 | 0.89 | PLA2G2A (0.45) | PLA2G2APLA2G1BKLK1KLKB1PLA2G10 | |
| SCHEMBL6889571 | 0.88 | PLA2G2A (0.44) | PLA2G2APLA2G1BKLK1KLKB1PLA2G10 | |
| SCHEMBL6776978 | 0.87 | PLA2G2A (0.42) | PLA2G2APLA2G1BKLK1PLA2G10PLA2G5 | |
| SCHEMBL6780031 | 0.87 | PLA2G2A (0.44) | PLA2G2APLA2G1BKLK1KLKB1PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |